Home
/
Entrada Therapeutics, Inc.
/
Financials
/
Quarterly
Entrada Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Entrada Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.61M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$1.95M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$20.56M
May 8, 2025
Q3
2025
Sep 30, 2024
$19.57M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$94.69M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$59.12M
May 8, 2025
Q3
2024
Sep 30, 2023
$43.74M
Nov 5, 2024
Q2
2024
Jun 30, 2023
$18.17M
Aug 13, 2024
Q1
2024
Mar 31, 2023
$25.26M
May 7, 2024
Q3
2023
Sep 30, 2022
$0
Nov 7, 2023
Q2
2023
Jun 30, 2022
$0
Aug 8, 2023
Q1
2023
Mar 31, 2022
$0
May 10, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($44.13M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
($43.10M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($43.10M)
Aug 6, 2025
Q2
2025
Mar 31, 2025
($17.35M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($17.35M)
May 8, 2025
Q3
2025
Mar 31, 2025
($17.35M)
Nov 6, 2025
Q3
2025
Sep 30, 2024
($14.03M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
$55.03M
Aug 6, 2025
Q3
2025
Jun 30, 2024
$55.03M
Nov 6, 2025
Q3
2025
Mar 31, 2024
$23.50M
Nov 6, 2025
Q1
2025
Mar 31, 2024
$23.50M
May 8, 2025
Q2
2025
Mar 31, 2024
$23.50M
Aug 6, 2025
Q3
2024
Sep 30, 2023
$35.46M
Nov 5, 2024
Q3
2024
Jun 30, 2023
($25.93M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($25.93M)
Aug 13, 2024
Q3
2024
Mar 31, 2023
($6.67M)
Nov 5, 2024
Q2
2024
Mar 31, 2023
($6.67M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($6.67M)
May 7, 2024
Q3
2023
Sep 30, 2022
($25.14M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($23.18M)
Aug 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($47.05M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($46.85M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($21.79M)
May 8, 2025
Q3
2025
Sep 30, 2024
($21.66M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
$53.42M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$21.11M
May 8, 2025
Q3
2024
Sep 30, 2023
$14.01M
Nov 5, 2024
Q2
2024
Jun 30, 2023
($16.30M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($5.78M)
May 7, 2024
Q3
2023
Sep 30, 2022
($25.94M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($23.58M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($22.15M)
May 10, 2023
Q3
2022
Sep 30, 2021
($14.36M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($9.91M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($8.39M)
May 12, 2022
Q3
2021
Sep 30, 2020
($6.97M)
Dec 9, 2021